* Phase II clinical trial activated * Cost control is still kept strict * We keep our fair value of SEK 0.
* Approval to initiate the financed TOTEMS study * Patient enrolment imminent Gabather has announced the initiation of the TOTEMS study, a ...
* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigger * We keep our fair value of SEK 0.
* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our...
CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Västra Hamnen's analyst Jacob Murat.
Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting...
Gabather tar ett viktigt steg framåt i utvecklingen av GT-002, en potentiell behandling för Frontallobsdemens (FTD), genom att inleda diskus...
Gabather, ett forskningsbolag specialiserade inom innovativa neurologiska terapier, inleder ett samarbete med MINDIG för att analysera EEG-d...
Gabather genomför mellan den 6–20 december en företrädesemission om 28,6 MSEK.
